Febuxostat versus allopurinol for gout [11]

New England Journal of Medicine

Volumn 354, Issue 14, 2006, Pages 1532-1533

  Gelber, Allan C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; ANTIGOUT AGENT; ENZYME INHIBITOR; THIAZOLE DERIVATIVE; XANTHINE OXIDASE;

CHRONIC KIDNEY FAILURE; DRUG EFFICACY; GOUT; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; NOTE; TREATMENT REFUSAL;

ALLOPURINOL; ENZYME INHIBITORS; GOUT; GOUT SUPPRESSANTS; HUMANS; THIAZOLES; TREATMENT REFUSAL; XANTHINE OXIDASE;

EID: 33645512778     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc053668     Document Type: Letter

References (4)

1. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-99.
2. Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987;316:1562-8.
3. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986;29:82-7.
4. Drazen JM. COX-2 inhibitors - a lesson in unexpected problems. N Engl J Med 2005;352:1131-2.